key: cord-356122-lzc1ux5z authors: Fedson, David DS. title: Statin treatment of COVID-19 date: 2020-09-28 journal: Am J Cardiol DOI: 10.1016/j.amjcard.2020.09.050 sha: doc_id: 356122 cord_uid: lzc1ux5z nan In a recent meta-analysis of four observational studies, Kow and Hasan reported that statins were 30% effective in reducing the severity or mortality of COVID-19 [1] [2] [3] [4] [5] . Since their report was published, two additional observational studies have appeared [6, 7] . Most of these six studies reported on statin treatment in reducing 30-day mortality (Table 1) . However, Kow and Hasan considered studies in which patients received statins either as outpatients or inpatients (Table 1) . For this reason, their estimate of statin effectiveness was probably imprecise. Statins are known to down regulate inflammatory cytokines and other biomarkers of inflammation [8] . Studies in human volunteers showed that these effects occur in a matter of a few hours or a day or two [9] . Moreover, in patients who have been taking statins, withdrawing treatment is followed by a rebound that increases both cytokine levels and mortality [10, 11] . Yan et al and Grasselli et al did not report on whether outpatient statin treatment was continued after hospital admission [2, 4] . A recent report of statins treatment by Gupta et al was also based on outpatient records (Table 1 ) [6] . In this study, only 77% of outpatient statin users continued treatment as inpatients, which means that 23% of the group of statin outpatient users were at risk of a rebound effect and increased mortality after hospital admission. This could have led to an underestimate of survival in patients who received statins as inpatients. Two of the four studies reported by Kow and Hasan were correctly based on inpatient statin treatment and both showed statistically significant improvement in survival (Table 1) [3, 5] . The smaller study by de Spiegleer et al also reported benefits in statin users among nursing home residents, but the result did not reach statistical significance [7] . The largest and most detailed study of inpatient statin treatment by Zhang et al also reported that inpatient treatment with angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) did not provide a survival benefit greater than that provided by statin treatment alone [5] . Nonetheless, several reports have shown that in hypertensive COVID-19 patients, outpatient or inpatient treatment with ACEIs or ARBs is not harmful [12] [13] [14] and, in some instances, these drugs actually improve survival [14] . In addition, inpatient ACEI/ARB treatment can reduce levels of inflammatory biomarkers [12] . Importantly, survival was significantly better in COVID-19 patients whose ACEI/ARB outpatient treatment was continued in the hospital compared with those whose treatment was discontinued [15] . This echoes the experience with statin withdrawal. Patients with COVID-19 experience severe endothelial dysfunction [16] . Statins and ARBs (and presumably ACEIs) have broad effects in maintaining or restoring normal endothelial cell function [17] . Combination treatment with both drugs has been suggested for cardiovascular diseases [18] and for emerging infectious diseases [17] , including Ebola and COVID-19 [19, 20] . These drugs primarily target the host response to infection [21] , not the viruses themselves [17] [18] [19] [20] 22] . Like dexamethasone, which has been shown in a randomized controlled trial to modestly improve survival in COVID-19 patients who require oxygen treatment or mechanical ventilation [23] , they are available worldwide as inexpensive generic drugs and could be used on the first pandemic day in any country that has a basic healthcare system. Several randomized controlled trials of statins, ACEIs and ARBs are planned or are underway for COVID-19 patients, but most of them will not report results until 2021. In the meantime, many physicians will feel an immediate need to offer effective treatments for their COVID-19 patients [24] . The studies of inpatient statin treatment are supported by solid experimental and clinical findings [17] , but it is unclear whether they provide a sufficient basis on which physicians can decide how to treat their patients. Nonetheless, the studies summarized in Table 1 , together with future observational reports on the effectiveness of inpatient treatment of COVID-19 patients with statins (and perhaps ACEIs/ARBs), will undoubtedly contribute to their treatment decisions. Disclosure The author has no conflicts of interest to disclose. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Meta-analysis of effectiveness of statins in patients with severe COVID-19 Role of drugs affecting the renin-angiotensin-aldosterone system on susceptibility and severity of COVID-19: a large case-control study from Zheijang Province Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19 The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents Pleiotropic effects of statins on the cardiovascular system Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality Statin withdrawal: clinical implications and molecular mechanisms Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID Continued in-hospital ACE inhibitor and ARB use in hypertensive COVID-19 patients is associated with positive clinical outcomes Overcoming barriers: the endothelium as a linchpin of coronavirus disease 2019 pathogenesis? Treating the host response to emerging virus diseases: lesson learned from sepsis, pneumonia, influenza and Ebola Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events A practical treatment for patients with Ebola virus disease Hiding in plain sight; an approach to treating patients with severe COVID-19 infection Pathogenesis of COVID-19 from the perspective of the Damage-Response Framework. mBio Statins: a viable candidate for host-directed therapy against infectious diseases Dexamethasone in hospitalized patients with Covid-19 -preliminary report Optimizing the trade-off between learning and doing in a pandemic